Breaking News

Financial Report: Bristol-Myers Squibb

January 28, 2016

Opdivo and Hep C franchise sales soar

Bristol-Myers Squibb
 
4Q Revenues: $4.3 billion (+1%)

4Q Loss: $129 million (earnings were $27 million 4Q14)

FY Revenues: $16.6 billion (+4%)

FY Earnings: $1.7 billion (-17%)

Comments: U.S. revenues increased 9% to $2.3 billion in the quarter. Opdivo sales were $475 million, up from $5 million in 4Q15. Eliquis sales were $602 million compared to $281 in 4Q14. Orencia sales were $540 million, up 22%. Baraclude sales were $309 million in the quarter, down 9% in the quarter. Hepatitis C Franchise sales were $458 million, compared to $207 million in 4Q14. R&D expenses increased 61% to $1.9 billion in the quarter due to higher charges resulting from business development transactions and an in-process research and development (IPRD) impairment.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks